Fig. 7: In vivo role of NOX4 in anoikis resistance and distant metastasis.

Data from tail vein injection model were shown in panels (a–g) and data from xenograft model were shown in panels (h–j). a Verifying of infection efficiency by fluorescence (magnification ×200). b Validation of knockdown efficiency of shRNA-NOX4 using western blot. c, d MKN-45-luciferase cells with or without NOX4 knockdown were tail vein injected into nude mice. c Bioluminescence imaging was performed with an IVIS Lumina XR at week 8. d Average luminescence intensity of each group at week 8. *P < 0.05. e Number of metastatic nodules in lungs of mice in group-shRNA-NOX4 and group-shRNA-NC. **P < 0.01. f Representative image of lung of mice in group-shRNA-NOX4 and group-shRNA-NC. Bars represent 5 mm for morphology and 200 μm for H&E staining. g Percentage of mice with metastasis in group-shRNA-NOX4 and group-shRNA-NC. h Image of tumors of mice in group-MKN45-AR, group-MKN45-AR + Plumbagin, group-MKN45 and group-MKN45 + Plumbagin. i Volume of tumor of mice in group-MKN45-AR, group-MKN45-AR + Plumbagin, group-MKN45 and group-MKN45 + Plumbagin at indicated time. j Weight of tumor of mice in group-MKN45-AR, group-MKN45-AR + Plumbagin, group-MKN45 and group-MKN45 + Plumbagin on 28th days. ***P < 0.001